News - Onyx Pharmaceuticals

Filter

Current filters:

Onyx Pharmaceuticals

Popular Filters

28 to 35 of 35 results

Onyx falls as FDA says no priority review for cancer drug

13-12-2011

US drugmaker Onyx Pharmaceuticals (Nasdaq: ONXX) saw its shares fall 7.1% to $37.76 in early trading…

carfilzomibNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulation

Bayer halts regorafenib trial for colorectal cancer on good Ph III results

27-10-2011

USA-based Bayer HealthCare Pharmaceuticals, a subsidiary of Germany’s Bayer AG (BAY: DE), has announced…

BayerOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibResearch

Bayer settles with Onyx over Nexavar and regorafenib with $160 million payment

13-10-2011

US drugmaker Onyx Pharmaceuticals (Nasdaq: ONXX) and German pharma major Bayer HealthCare, a unit of…

BayerLegalLicensingNexavarOncologyOnyx PharmaceuticalsPharmaceuticalregorafenib

Onyx Pharma files NDA for multiple myeloma drug carfilzomib

29-09-2011

California, USA-based Onyx Pharmaceuticals (Nasdaq: ONXX) says it has completed the New Drug Application…

carfilzomibNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulation

Executive changes at Onyx Pharma and XOMA

02-09-2011

Onyx Pharmaceuticals (Nasdaq: ONXX) has appointed Helen Torley as executive vice president and chief…

ManagementOnyx PharmaceuticalsPharmaceuticalXOMA Corp

Low-dose sorafenib may improve therapy for head and neck cancer, Ohio researchers find

17-05-2011

Adding low doses of the targeted agent sorafenib (German drug major Bayer and Onyx’ kidney and liver…

BayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearch

28 to 35 of 35 results

Back to top